Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
|ClinicalTrials.gov Identifier: NCT00008190|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : February 4, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation and interleukin-2 in treating patients who have acute leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: aldesleukin Biological: filgrastim Drug: busulfan Drug: cyclophosphamide Drug: etoposide Drug: melphalan Procedure: peripheral blood stem cell transplantation||Phase 2|
- Determine the efficacy of busulfan, cyclophosphamide, and etoposide followed by autologous peripheral blood stem cell transplantation and interleukin-2 in patients with high-risk acute leukemia.
- Determine the efficacy of immunomodulatory therapies in terms of relapse-free survival of these patients treated with this regimen.
- Determine the hematopoietic reconstitution, relapse, and survival of these patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Following a course of mobilization chemotherapy, patients receive priming therapy comprising filgrastim (G-CSF) and interleukin-2 through the completion of leukapheresis. Patients then receive oral busulfan 4 times daily on days -8 through -5, cyclophosphamide IV continuously on days -4 and -3, and etoposide IV over 2 hours on day -4. For patients unable to receive cyclophosphamide and etoposide, melphalan IV is administered instead on days -3 and -2. Autologous peripheral blood stem cells (PBSC) are reinfused on day 0.
Patients then receive G-CSF daily beginning on day 0 and continuing until blood counts recover followed by interleukin-2 subcutaneously daily beginning at the completion of G-CSF therapy and continuing for 6 months.
Patients are followed weekly for 1 month and then monthly thereafter.
PROJECTED ACCRUAL: A total of 19-25 patients will be accrued for this study within 3-5 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia|
|Study Start Date :||March 1999|
|Actual Primary Completion Date :||November 2005|
|Actual Study Completion Date :||May 2008|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00008190
|United States, New York|
|Herbert Irving Comprehensive Cancer Center at Columbia University|
|New York, New York, United States, 10032|
|Study Chair:||Charles S. Hesdorffer, MD||Herbert Irving Comprehensive Cancer Center|